Outpatient Transurethral Resections of Bladder Tumors: Insights from the Largest Cohort to Date
Urologia Internationalis · 2025
DOI: 10.1159/000543979 ↗Kurz gefasst
Fachartikel in der Zeitschrift Urologia Internationalis, 2025. Verfasst von Maxime Pattou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Urology department, APHP, Saint Louis Hospital, Paris, France. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Ambulatory Surgical Procedures, Cystectomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Introduction
Outpatient transurethral resection of bladder tumors (TURBT) is not widespread, involving only 5% of patients. Our aim was to assess the feasibility of TURBT in an outpatient setting and to evaluate factors possibly associated with conversion to inpatient care.
Methods
All consecutive outpatient-TURBT performed between January 2016 and December 2022 in one academic center was retrospectively analyzed. Outpatient success was defined as the absence of conversion to conventional hospitalization as well as the absence of unscheduled care within 30 postoperative days. The quality of the resection was assessed by the presence of detrusor muscle in the surgical specimen.
Results
A total of 500 consecutive outpatient-TURBT were included in 376 patients. Outpatient-TURBT was performed for primary tumor diagnosis in 187 (37%) cases, second look in 66 (13%) cases and tumor relapse in 216 (43%) cases. Muscle was present in 86% of cases. Perioperative inpatient conversions occurred in 40 cases (8%). Once converted, patients stayed a median of 2 days IQR (1;3). Seventy-seven post-TURBT unscheduled care were observed (15%) with 40 emergency room visits (8%) and/or 22 rehospitalizations (4%), occurring on a median postoperative day 3 IQR (1; 4). Overall complication rate was 11% (51 cases of grade 1 and 2 complications [10%] and 6 cases of grade 3 complications [1%]). Multivariate predictors of outpatient-TURBT failure were specimen weight ≥1 g (OR = 4.35, 95% CI: 1.60–13.3, p = 0.007), surgery duration (OR = 1.03, 95% CI: 1.06–1.71), p = 0.002) and antiplatelet treatment (OR = 2.86, 95% CI: 0.864–9.17, p = 0.077).
Conclusion
Outpatient TURBT appears to be acceptable with an 8% conversion rate, as well as safe, with an 11% complication rate. Quality of the resection was not affected by the outpatient setting. Tumor weight ≥1 g, surgery duration and absence of antiplatelet treatment were significant multivariate predictors of outpatient surgery failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Urology department, APHP, Saint Louis Hospital, Paris, France.
- Pathology department, APHP, Saint Louis Hospital, Paris, France.
- Urology department, APHP, Saint Louis Hospital, Université Paris Cité, Paris, France.
Zitieren
APA
Pattou, M., Ochoa, A., Goujon, A., Verine, J., Meyer, F., Bebane, S., Gaudez, F., Meria, P., Desgrandchamps, F., Mongiat-Artus, P., & Masson-Lecomte, A. (2025). Outpatient Transurethral Resections of Bladder Tumors: Insights from the Largest Cohort to Date. Urologia Internationalis. https://doi.org/10.1159/000543979
Vancouver
Pattou M, Ochoa A, Goujon A, Verine J, Meyer F, Bebane S, et al. Outpatient Transurethral Resections of Bladder Tumors: Insights from the Largest Cohort to Date. Urologia Internationalis. 2025. doi:10.1159/000543979
BibTeX
@article{Pattou2025,
author = {Pattou, Maxime and Ochoa, Adrien and Goujon, Annabelle and Verine, Jérôme and Meyer, François and Bebane, Sonia and Gaudez, François and Meria, Paul and Desgrandchamps, François and Mongiat-Artus, Pierre and Masson-Lecomte, Alexandra},
title = {Outpatient Transurethral Resections of Bladder Tumors: Insights from the Largest Cohort to Date},
journal = {Urologia Internationalis},
year = {2025},
doi = {10.1159/000543979}
}
EUVIMED